| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 14, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)
S-8 - SeaStar Medical Holding Corp (0001831868) (Filer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
– Company advancing clinically proven platform therapy, the Selective Cytopheretic Device (SCD), to address the life-threatening consequences of hyperinflammation – SCD lead program in Acute Kidney Injury (AKI) with potential FDA approval for pediatric AKI targeted for Q1 2023 and commencement of pivotal trial in adult AKI targeted in Q1 2023 – Ongoing exploratory clinical research to refine patient populations where SCD may be effective to fuel pipeline with potential in high-value hyperinflammatory indications– SeaStar Medical commenced trading on Nasdaq under the ticker "ICU" today, Monday, October 31st Denver, Colorado, Oct. 31, 2022 (GLOBE NEWSWIRE) -- SeaStar Med
LMF Acquisition Opportunities Renamed SeaStar Medical Holding Corporation SeaStar Medical Holding Corporation Common Stock and Warrants to Commence Trading on Nasdaq Under New Ticker Symbol "ICU" and "ICUCW" DENVER and TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that it has completed its previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA). The business combination closed on October
DENVER and TAMPA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA), and SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that LMAO stockholders voted to approve the previously proposed business combination with SeaStar Medical at LMAO's special meeting of LMAO stockholders (the "Special Meeting") held earlier today, October 18, 2022. More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Med
TAMPA, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ:LMFA) ("LM Funding" or "LMFA"), a technology-based specialty finance company, today announced its financial results for the three and six months ended June 30, 2021. Financial Highlights for the Three and Six Month Period Ended June 30, 2021: Net income attributable to LM Funding for the three and six-month periods ended June 30, 2021 totaled $11.1 million or $2.05 per basic and diluted share and $15.5 million or $2.96 per basic and $2.95 per diluted share, respectively.Cash increased to $22.2 million or approximately $4.09 per basic and diluted share on June 30, 2021 as compared to $11.6 million
Denver, Colo. and Tampa, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced the appointment of Dr. Sai Prasad N. Iyer, Ph.D to the position of Vice President, Medical Affairs and Clinical Development at SeaStar Medical, effective September 15, 2022. Dr. Iyer brings 20 years of industry experience and will provide leadership in developing and executing clinical trials, including SeaStar Medical's upcoming pivotal clinical trial of its Sel
DENVER, CO and TAMPA, FL, May 24, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced that Kevin Chung, MD will join SeaStar Medical as Chief Medical Officer (CMO), effective July 1, 2022. Dr. Chung brings over 20 years of experience as an accomplished critical care physician with expertise in extracorporeal life support therapies (ECLS). Since his fellowship training in critical care at Walter Reed Army Medical Center, Dr. Chung has treated thousands o
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)